Corcept Therapeutics Incorporated (CORT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corcept Therapeutics Incorporated (CORT)

CORT 72.91

-0.8%

12:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (14)	10/27/2004 3:50:58 AM
From: tuck	Read Replies (1) of 32

Well, this will take a little uncertainty out of CORT's story: >>MENLO PARK, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Corcept Therapeutics Incorporated, (Nasdaq: CORT - News), today announced that it has resolved a previously disclosed issue relating to inventorship under a patent exclusively licensed by the company from Stanford University. The patent in question covers the use of GR-II antagonists to treat psychotic features of Psychotic Major Depression (PMD). Under the resolution Corcept will retain its exclusive rights under the patent, and no additional payments under the license will be required.<< snip I wouldn't expect this to protect it from lock up expiration blues, however. Cheers, Tuck Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next